Acne Drugs Market Size Is Predicted To Reach $5.9 Billion By 2025

The global acne drugs market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR during the forecast period. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.

Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.

Full Research Report On Acne Drugs Market Visit Here: https://www.grandviewresearch.com/industry-analysis/acne-drugs-market

Further key findings from the report suggest:

• By type, inflammatory acne captured more than 50.0% of the market in 2017. Comedonal acne were ranked second-largest, among other types
• On the basis of therapeutic class, retinoids led the market in 2017, followed by antibiotics. This trend is likely to continue through 2025
• The treatment paradigm is shifting toward combination therapies and biologics. Combination products are gaining traction due to higher efficacy, convenient dosing, and fewer adverse effects
• Topical products dominated the treatment landscape, based on mode of administration. However, introduction of biologics is likely to result in the growth of the injectables segment
• U.S. dominated the major markets and is projected to maintain its lead through 2025, owing to rising disease incidence and ease of access to anti-acne products
• Allergan, Bayer, Galderma, Stiefel, and Valeant are some key players operating in this market. Valeant is projected to lead the market in 2025 due to higher adoption of Retin-A micro as well as anticipated launch of pipeline candidates.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/acne-drugs-market/request/rs1

Grand View Research has segmented the global acne drugs market based on type, therapeutic class, mode of administration, and country:

Acne Drugs Type Outlook (Revenue, USD Million, 2017 - 2025)

• Comedonal
• Inflammatory
• Cystic
• Post-surgical/Wound

Acne Drugs Therapeutic Class Outlook (Revenue, USD Million, 2017 - 2025)

• Retinoid
• Antibiotic
• Hormonal Agent
• Combination
• Others

Acne Drugs Mode of Administration Outlook (Revenue, USD Million, 2017 - 2025)

• Topical
• Oral
• Injectable

Acne Drugs Country Outlook (Revenue, USD Million, 2017 - 2025)

• U.S.
• U.K.
• Germany
• Spain
• France
• Italy
• Japan

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Surgical Retractors Market Size, Share, Demand, Future Growth Insights And Ongoing Trends

The global surgical retractors market size is expected to reach USD 1.81 billion by 2025, according to a new report by Grand View Research, Inc., registering a 3.2% CAGR over the forecast period. The market is primarily driven by unprecedented upsurge in surgical volume over the past few years. According to data published by WHO, the global surgical volume was estimated at 312.9 million in 2012 from 226.4 million in 2004. The statistics also showed that the mean global surgical rate is approximately 4,469 surgeries per 100,000 population per year. These numbers exemplify the widening scope of surgery and adoption of retractors.

Increase in number of cesarean surgeries has fueled demand for C-section retractors. As per the American Medical Association, adoption rate of cesarean surgeries is around 19.0% globally. Technological developments, such as automation in surgical instruments, are improving minimally invasive surgeries, thus creating high growth potential for the market. For instance, advent of atraumatic laparoscopic retractors and 3D retractors has ensured greater safety during surgeries and reduced post-operative complications.

Full Research Report On Surgical Retractors Market Visit Here: https://www.grandviewresearch.com/industry-analysis/surgical-retractors-market

Surgical Retractors Market Report Highlights

• By type, hand-held retractors accounted for the largest share in 2017 as a result of advantages such as low cost of product handling, storage, and maintenance. Self-retaining retractors are predicted to exhibit lucrative growth owing to greater convenience associated with them
• On the basis of product, orthopedic retractors held a considerable share in 2017 owing to increasing incidence of orthopedic disorders in bariatric and geriatric patients
• Obstetrics and gynecology dominated the market based on application owing to upsurge in number of C-section surgeries and gynecological preventive examinations globally
• In 2017, North America held a substantial market share owing to growing prevalence of chronic diseases and presence of highly advanced medical infrastructure. Adoption of technologically advanced products is also presenting high growth prospects
• The market in Asia Pacific is anticipated to witness significant growth owing to improving healthcare systems, rising healthcare expenditure, and growing awareness
• Key companies include Teleflex, Johnson & Johnson, B.Braun, Medtronic, Thompson Surgical, and Becton, Dickinson and Company
• The market is highly competitive with key participants consistently deploying strategies such as mergers and acquisitions to gain competitive advantage. For instance, in April 2017, Teleflex acquired Pyng Medical to gain a leadership position and expand its product portfolio.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/surgical-retractors-market/request/rs1

Surgical Retractors Market Segmentation

Grand View Research has segmented the global surgical retractors market on the basis of type, product, application, end use, and region:

Surgical Retractors Type Outlook (Revenue, USD Million, 2014 - 2025)

• Hand-held
• Self-retaining

Surgical Retractors Product Outlook (Revenue, USD Million, 2014 - 2025)

• Abdominal
• Finger
• Nerve
• Orthopedic
• Rectal
• Thoracic
• Ribbon
• Others

Surgical Retractors Application Outlook (Revenue, USD Million, 2014 - 2025)

• Neurosurgery
• Wound Closure
• Reconstructive Surgery
• Cardiovascular
• Orthopedic
• Obstetrics & Gynecology
• Others

Surgical Retractors End-use Outlook (Revenue, USD Million, 2014 - 2025)

• Hospitals
• Ambulatory Surgical Centers
• Others

Surgical Retractors Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Asia Pacific
• Japan
• China
• India
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Image-guided Therapy Systems Market Size, Share, Demand, Future Growth Trends

The global image-guided therapy systems market size is expected to reach USD 4.95 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to exhibit a healthy CAGR of 6.3% during the forecast period. Growing geriatric population base and cases of chronic diseases are expected to boost the market demand. Other factors propelling market growth include a rising preference for minimally invasive surgeries and technological advancements in image-guided therapy systems. Various initiatives undertaken in the area of cancer radiotherapy is also one of the important factors driving the market.

New product launches by major companies are also having a positive impact on market development. For instance, in February 2017, Philips launched a next-generation image-guided therapy platform called Azurion for advancing patient care. The growing adoption of such advanced systems is expected to drive the market. The development of this system was aimed at optimizing interventional lab performance, thereby ensuring superior care delivery. The increasing number of initiatives undertaken by public and private firms in the area of cancer radiotherapy is also estimated to have a positive impact on the market growth.

In addition, many academic institutions are also investing in cancer radiotherapy projects for increasing the effectiveness of treatment therapies. This is also likely to contribute to market expansion. The development of the Image-guided Therapy Program by the Brigham and Women’s Hospital aimed at advancing imaging and therapeutic technologies for developing minimally invasive surgical and interventional techniques is an example of one such initiative.

Full Research Report On Image-guided Therapy Systems Market Visit Here: https://www.grandviewresearch.com/industry-analysis/image-guided-therapy-systems-market

Image-guided Therapy Systems Market Report Highlights

• Endoscopes segment accounted for the largest revenue share in 2017 owing to technological advancements, high volume of endoscope-guided surgeries, and rising preference for minimally invasive surgeries
• Cardiac surgery emerged as the largest application segment in 2017. This growth is attributed to the rising prevalence of target diseases, preference for minimally invasive cardiac surgeries, and R&D initiatives aimed at developing real-time cardiac interventions systems
• Hospitals emerged as the largest end-use segment in 2017. However, Ambulatory Surgery Centers (ASCs) segment is projected to expand at the fastest CAGR of 7.3% over the forecast period
• North America emerged as the largest regional market. Asia Pacific is anticipated to exhibit the fastest growth rate of 7.6% during the forecast period
• The market is consolidated with the presence of Koninklijke Philips N.V., Siemens Healthineers, GE Healthcare, and Fujifilm Holdings Corporation accounting for the majority market share. Analogic Corporation; Varian Medical Systems, Inc.; Brainlab AG; Medtronic PLC; and Stryker Corp. are several other prominent companies in the market.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/image-guided-therapy-systems-market/request/rs1

Image-guided Therapy Systems Market Segmentation

Grand View Research has segmented the global image-guided therapy systems market on the basis of product, application, end use, and region:

Image-guided Therapy Systems Product Outlook (Revenue, USD Million, 2014 - 2025)

• Computed Tomography (CT) Scanners
• Ultrasound Systems
• Magnetic Resonance Imaging (MRI)
• Endoscope
• X-ray Fluoroscopy
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)

Image-guided Therapy Systems Application Outlook (Revenue, USD Million, 2014 - 2025)

• Cardiac Surgery
• Neurosurgery
• Orthopedic Surgery
• Urology
• Gastroenterology
• Oncology Surgery
• Others

Image-guided Therapy Systems End-use Outlook (Revenue, USD Million, 2014 - 2025)

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Clinics
• Research & Academic Institutes

Image-guided Therapy Systems Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• The U.S.
• Europe
• Germany
• The U.K.
• France
• Russia
• Italy
• Spain
• Netherlands
• Sweden
• Asia Pacific
• China
• India
• Australia
• Singapore
• Latin America
• Brazil
• Middle East & Africa
• South Africa
• Saudi Arabia

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Sarcoma Drugs Market Size Is Estimated To Reach $1.2 Billion By 2023

The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The introduction of targeted therapy has revolutionized the treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Full Research Report On Sarcoma Drugs Market Visit Here: https://www.grandviewresearch.com/industry-analysis/sarcoma-drugs-market

Further key findings from the report suggest:

• EU5 will remain the second largest market with more than 30% share by 2023. The growth of the segment can be attributed to the rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
• Eli Lilly’s Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
• Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
• The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
• Companies with late-stage pipeline products for sarcoma are likely to enter the market by 2019 and would capture more than 10.0% of the sarcoma market share in 2023
• Drugs with novel targets in early-phase development include Novartis’s Afinitor (mTOR inhibitor), Tesaro’s Zejula (PARP inhibitor), Amgen’s Imlygic (gene therapy), and Pfizer’s Crizotinib (ALK and MET tyrosine kinases inhibitor)
• The role of VEGF inhibitors and mTOR inhibitors is under evaluation in multiple early phase trials. However, no statistically significant data has been reported to date

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/sarcoma-drugs-market/request/rs1

Grand View Research has segmented the global sarcoma drugs market based on treatment type and region:

Sarcoma Drugs Treatment Class Outlook (Revenue, USD Million, 2017 - 2023)

• Chemotherapy
• Targeted Therapy

Sarcoma Drugs Country Outlook (Revenue, USD Million, 2017 - 2023)

• The U.S.
• The U.K.
• Germany
• France
• Italy
• Spain
• Japan

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Life Science Analytics Market Size, Share, Demand, Future Growth Analysis And Trends By 2025

The global life science analytics market size is expected to reach USD 25.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 12.9% during the forecast period. Increasing digitalization in pharma and life sciences industry to improve its value chain is one of the key factors anticipated to boost the market over the forecast period. In addition, reducing R&D productivity and increasing regulatory oversights are some of the factors expected to drive this market.

Rising healthcare cost is one of the crucial factors anticipated to positively impact the life science analytics market. Developing as well as developed regions are facing many challenges in providing cost-effective and qualitative care. According to various reports, approximately 70.0% of the geriatric population is expected to use some kind of long-term care during their lifetime. Based on the abovementioned scenario in 2017, on an average, a retired couple is anticipated to spend over USD 275,000 in healthcare throughout their lifetime. Moreover, political instability, economic stress, and lack of proactive initiatives may result in low healthcare funding.

Some of the key factors anticipated to boost global healthcare cost are growing number of claims pertaining to non-communicable diseases, priority for wellness at workplaces, and growing focus on wellness among adult and geriatric population. Growing healthcare cost is expected to boost demand for life science analytics to streamline third-party processes and optimize overall cost.

Adoption of big data analytics in the life sciences industry allows government and healthcare providers to identify high-risk population for preventive care measures and compare effective treatment procedures to evaluate relative cost of care, thereby reducing overall cost and improving quality of care. For instance, in 2011, the Arkansas Healthcare Payment Improvement Initiative (AHCPII) saved nearly USD 720 million while expanding its coverage to uninsured individuals in U.S.

Advanced methods such as predictive analytics are widely used in healthcare financing systems primarily to avoid frauds in payments. For instance, in 2011, CMS reported that under its Fraud Prevention System (FPS), predictive analytics helped save USD 1.5 billion by preventing frauds and improper payments. Moreover, CMS is developing next-generation predictive analytics, which is expected to boost its usage across applications.

Full Research Report On Life Science Analytics Market Visit Here: https://www.grandviewresearch.com/industry-analysis/life-science-analytics-market

Life Science Analytics Market Report Highlights

• As of 2016, reporting was most widely used type and thus held nearly 30.0% share in the global market
• In 2016, sales and marketing support held the largest share in the global market owing to higher adoption of analytics in the life sciences industry for sales activities
• Some of the key players operating in this market are Accenture; Cognizant; IBM Corporation; Oracle; SAS Institute, Inc.; Wipro Limited; IQVIA; and TAKE Solutions Limited.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/life-science-analytics-market/request/rs1

Life Science Analytics Market Segmentation

Grand View Research has segmented the global life science analytics market report on the basis of type, component, application, delivery, and region:

Type Outlook (Revenue, USD Million, 2014 - 2025)

• Reporting
• Descriptive
• Predictive
• Prescriptive

Component Outlook (Revenue, USD Million, 2014 - 2025)

• Software
• Services

Application Outlook (Revenue, USD Million, 2014 - 2025)

• Research and Development
• Sales and Marketing
• Regulatory Compliance
• Supply Chain Analytics
• Pharmacovigilance

Delivery Outlook (Revenue, USD Million, 2014 - 2025)

• On-demand
• On-premises

Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Mexico
• MEA
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com